LivaNova PLC (LIVN)
- Previous Close
51.23 - Open
51.08 - Bid 50.74 x 100
- Ask 50.81 x 100
- Day's Range
50.31 - 51.15 - 52 Week Range
42.75 - 64.47 - Volume
776,926 - Avg. Volume
684,492 - Market Cap (intraday)
2.756B - Beta (5Y Monthly) 1.00
- PE Ratio (TTM)
-- - EPS (TTM)
-0.31 - Earnings Date Oct 30, 2024 - Nov 4, 2024
- Forward Dividend & Yield --
- Ex-Dividend Date --
- 1y Target Est
71.89
LivaNova PLC, a medical device company, designs, develops, manufactures, and sells therapeutic solutions worldwide. The company operates through Cardiopulmonary, Neuromodulation, and Advanced Circulatory Support segments. The Cardiopulmonary segment develops, produces, and sells cardiopulmonary products, including oxygenators, heart-lung machines, autotransfusion systems, perfusion tubing systems, cannulae, connect, and other related products. The Neuromodulation segment designs, develops, markets, and sells VNS Therapy System, an implantable pulse generator and connective lead that stimulates the vagus nerve; difficult-to-treat depression and drug-resistant epilepsy devices. The Advanced Circulatory Support segment develops, produces, and sells temporary life support products. It serves perfusionists, neurologists, neurosurgeons, and other physicians, as well as hospitals, other medical institutions, and healthcare providers. The company sells its products through direct sales representatives and independent distributors. LivaNova PLC was incorporated in 2015 and is headquartered in London, the United Kingdom.
www.livanova.comRecent News: LIVN
View MorePerformance Overview: LIVN
Trailing total returns as of 9/20/2024, which may include dividends or other distributions. Benchmark is .
YTD Return
1-Year Return
3-Year Return
5-Year Return
Compare To: LIVN
Select to analyze similar companies using key performance metrics; select up to 4 stocks.
Statistics: LIVN
View MoreValuation Measures
Market Cap
2.76B
Enterprise Value
3.10B
Trailing P/E
--
Forward P/E
20.88
PEG Ratio (5yr expected)
0.46
Price/Sales (ttm)
2.28
Price/Book (mrq)
2.22
Enterprise Value/Revenue
2.57
Enterprise Value/EBITDA
325.29
Financial Highlights
Profitability and Income Statement
Profit Margin
-1.37%
Return on Assets (ttm)
3.34%
Return on Equity (ttm)
-1.34%
Revenue (ttm)
1.21B
Net Income Avi to Common (ttm)
-16.59M
Diluted EPS (ttm)
-0.31
Balance Sheet and Cash Flow
Total Cash (mrq)
329.24M
Total Debt/Equity (mrq)
54.53%
Levered Free Cash Flow (ttm)
132.39M